Hepatic resection and blood transfusion increase morbidity after cytoreductive surgery and HIPEC for colorectal carcinomatosis

  title={Hepatic resection and blood transfusion increase morbidity after cytoreductive surgery and HIPEC for colorectal carcinomatosis},
  author={C. Soldevila-Verdeguer and Juan J. Segura-Sampedro and C. Pine{\~n}o-Flores and P. Sanchis-Cort{\'e}s and X. Gonz{\'a}lez-Argent{\'e} and R. Morales-Soriano},
  journal={Clinical and Translational Oncology},
Background and objectives Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective but complex treatment for peritoneal metastasis (PM). Our objective was to identify risk factors for postoperative morbidity and mortality following CRS-HIPEC. Methods Retrospective study of prospectively collected data of patients undergoing CRS-HIPEC for PM arises from colorectal cancer between January 2008 and December 2017. Perioperative variables were correlated with… Expand

Figures and Tables from this paper


Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
To assess the influence of parietal and visceral peritonectomy procedures on moderate/severe morbidity in patients undergoing surgical cytoreducion and hyperthermic intraperitoneal chemotherapy and to identify subgroups of patients at highest operative risk, a prospective database of 426 combined procedures was reviewed. Expand
Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis
This study identifies postoperative complications requiring intervention as the only significant risk factor for early recurrence, independent of the extent of peritoneal disease, highlighting the importance of minimizing the risk of postoperative complication. Expand
Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery
Although patients with colonic PM undergoing CRS + HIPEC treatment were younger and healthier, the postoperative outcome was worse, and the need for adequate case-mix correction in colorectal surgery audits is stressed. Expand
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution
The authors' single institution experience of CRS/HIPEC procedures for peritoneal carcinomatosis demonstrates acceptable perioperative outcome and long-term survival and this series supports the safety of C RS-HipEC in selected patients. Expand
Morbidity and Mortality of Cytoreduction with Intraperitoneal Chemotherapy: Outcomes from the ACS NSQIP Database
In this nationwide cohort, the death and morbidity rate associated with cytoreduction and IPC is consistent with other large series and may help guide patient selection, counseling, and preoperative optimization before IPC. Expand
Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei
CRS and PIC has an acceptable rate of perioperative mortality and morbidity in selected patients with PMP. Expand
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Presence of symptoms, CCI, and prior resection status predict major complications and define a low-risk population after CRS-HIPEC, a single-institution database study. Expand
Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study
There is a great variability in the intraoperative fluid therapy needs of the patients and the use of a hemodynamic goal-directed anesthetic protocol in CRS and HIPEC enables to individually adjust the fluid therapy, avoiding over-hydration and ensuring hemodynamic stability in all surgery phases. Expand
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.
The limited data that exists suggests that the independent contribution of the heated intraperitoneal chemotherapy to CRS and HIPEC morbidity is relatively small. Expand
Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
Cytoreductive surgery and performing HIPEC by experienced groups in selected patients aged ≥75 years can be performed with morbidity and mortality similar to that described in the literature. Expand